Predicting benefit from maintenance durvalumab after firstline chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assay
Fong, C. Y. K. Iyer, S. Potts, L. Peckitt, C. Cromarty, S. Saffery, C. Kidd, S. Rana, T. Ausec, L. Gregorc, A.
Fong, C. Y. K.
Iyer, S.
Potts, L.
Peckitt, C.
Cromarty, S.
Saffery, C.
Kidd, S.
Rana, T.
Ausec, L.
Gregorc, A.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Fong CYK, Iyer S, Potts L, Peckitt C, Cromarty S, Saffery C, et al. Predicting benefit from maintenance durvalumab after firstline chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assay. Annals of Oncology. 2022 Sep;33(7):S1110-S. PubMed PMID: WOS:000866211601487.